Last updated: May 30, 2026
Sugammadex Sodium Suppliers: Who Manufactures, Provides APIs, and Controls Supply for Branded and Generic Markets
Sugammadex sodium supply is concentrated in a small number of manufacturers that can reliably produce the sterile, GMP-grade active pharmaceutical ingredient and, in many cases, the finished injectable dosage form. For procurement, the key distinction is whether a supplier sells (1) sugammadex sodium API, (2) ready-to-fill sterile bulk drug product, or (3) fully packaged finished drug product under contract manufacturing. Many market-facing “suppliers” are distributors or CMOs rather than the underlying molecule producer.
Supply map (practical procurement view)
- API manufacturers: limited producers with validated chemistry for sugammadex sodium and capacity for GMP batches.
- Sterile injectable manufacturers / contract fillers: players that produce or fill the finished injectable (typically vials) under GMP and manage aseptic processing.
- Finished-dose commercial supply: originator and authorized generics sourced from manufacturers with regulatory-ready dossiers (e.g., EU/US approvals).
- Distributors: marketing companies that trade product produced by the above categories.
Who supplies sugammadex sodium API, and which companies manufacture the molecule?
The supplier set that matters for API procurement is the set that controls the actual GMP batch of sugammadex sodium, not reseller inventory. In procurement terms, these are typically established chemical manufacturers with dossier history for parenteral use.
What to treat as “API suppliers” vs “product suppliers”
- API supplier: sells sugammadex sodium as an API, typically with a DMF/ASMF-to-customer linkage for regulatory submissions.
- Finished product supplier: provides the injection (vials) where the aseptic and packaging steps are controlled.
- CMO sterile supplier: produces sterile drug product and/or performs filling and packaging for a brand or label holder.
Procurement implication: If the target is an injectable finished dosage form, the practical constraint is sterile aseptic manufacturing capability and regulatory alignment, not just chemical API sourcing.
Which companies contract manufacture sugammadex sodium injections or vials?
Contract manufacturing is the most common route for market entrants to secure sterile injectable supply without building aseptic capacity from scratch. For sugammadex sodium, contract sterile manufacturing covers:
- sterile bulk drug product (drug substance to sterile drug product conversion),
- vial filling,
- rubber closure and aluminum seal supply coordination,
- end-to-end packaging under GMP.
Procurement implication: For payer-linked sourcing or tendering, the contract manufacturer name is often less visible than the “MAH” (marketing authorization holder) or distributor name, but it is critical for continuity and quality consistency.
What finished suppliers are present for sugammadex sodium in the US and EU?
For high-value procurement, the fastest way to map “who supplies what” is to tie sugammadex sodium to:
- the approved finished products marketed under the regulatory framework in the relevant territory, and
- the manufacturing sites listed on product labeling and regulatory documents.
Procurement implication: A tender response must specify both the finished-dose manufacturer and the fill/finish site (when different), because those drive availability, lead time, and recall risk.
How many sugammadex sodium suppliers are there, and why is supply concentrated?
Sugammadex sodium has supply concentration driven by:
- sterile injectable GMP requirements (for finished products),
- specialized purification and particle specification for consistent performance,
- scale constraints for a niche anesthesiology drug,
- regulatory dossier complexity (DMF/ASMF and site qualifications).
Procurement implication: Supplier diversification is limited. Most buyers mitigate risk via dual sourcing across:
- API vs finished-dose,
- different fill/finish sites,
- and alternate distributor channels for inventory buffering.
What supply-chain risk factors affect sugammadex sodium availability?
Key risk drivers in tendering and manufacturing planning:
- aseptic fill capacity constraints,
- single-site recall events (closure integrity, sterility failures, particulates),
- lead-time variability for vials, stoppers, and seals,
- regulatory deviations that pause batch release,
- import lane delays for finished vials versus bulk sterile.
Procurement implication: Buyers should qualify suppliers on:
- change control history (manufacturer site changes, sterilization method changes),
- batch release timing,
- reserve stock or supply agreements for critical months.
How do sugammadex sodium suppliers differ by dosage strength and packaging?
Common market requirements for sugammadex sodium include:
- specific vial strengths,
- total deliverable volume per vial,
- packaging format (cartons, hospital multipacks),
- compatibility with IV infusion protocols used by hospitals.
Procurement implication: A supplier offering the API does not guarantee readiness for the exact hospital-ready vial format. Conversely, a finished-dose supplier may not support custom packaging or alternate vial sizes.
Which licensing and regulatory holders control supply of branded sugammadex products?
Supply and sourcing are often shaped by the marketing authorization holder (MAH) structure:
- Originator MAH controls manufacturing authorizations and release workflows in each territory.
- Authorized generics may use alternative manufacturing sites and different label claims.
- Distributor networks control inventory availability and tender delivery.
Procurement implication: For multi-country procurement, a tender can require the MAH name, not only the plant. That affects eligibility and delivery assurances.
What generic and biosimilar-like entry risks exist for sugammadex sodium suppliers?
Sugammadex sodium is a small-molecule parenteral drug, so the relevant “entry” risks are generics, not biosimilars. Supplier risk includes:
- lower-cost manufacturing that may rely on limited aseptic capacity,
- staggered approvals leading to uneven market supply,
- substitution policies by health systems affecting demand concentration.
Procurement implication: Generic competition can reduce price but also increases supply instability if new entrants rely on a single fill/finish site.
Who are the likely supplier categories for sugammadex sodium tenders?
When building a supplier shortlist for tenders, the operational categories are:
- API producer (chemical GMP) for upstream supply security.
- Sterile drug product/finish manufacturer for ready-to-distribute injectable.
- Finished-dose MAH or local distributor for market eligibility and distribution terms.
- Multi-country importers for tariff and logistics continuity.
Procurement implication: The most stable tenders use two-layer qualification: upstream API assurance plus downstream sterile fill capacity.
Key takeaways
- Sugammadex sodium supply is concentrated because sterile injectable manufacturing and regulatory dossier readiness limit the number of qualified suppliers.
- “Supplier” in procurement should be defined by what is being bought: API, sterile bulk/finished vials, or distribution inventory.
- Supplier qualification should prioritize the actual manufacturing and aseptic fill/finish site, not only the distributor name.
- Availability risk is driven by fill/finish capacity, batch release consistency, and component lead times (vials, stoppers, seals).
FAQs
-
What is the difference between sugammadex sodium API suppliers and finished injection suppliers?
API suppliers provide the active substance; finished injection suppliers provide sterile vials ready for clinical distribution, typically with aseptic fill/finish under GMP.
-
Can a contract manufacturer supply both sugammadex sodium API and sterile injectable vials?
Some suppliers cover both upstream and sterile operations, but many specialize in either API chemistry or sterile fill/finish.
-
What matters most for hospital procurement of sugammadex sodium?
Vial strength, sterility assurance, batch release timing, and consistent packaging formats.
-
How do import and distribution channels affect sugammadex sodium availability?
Lead times and import lane stability impact delivery more for finished vials than for API, because aseptic product has tighter release and shelf-life constraints.
-
What supplier criteria reduce recall and disruption risk for injectable sugammadex sodium?
Qualification of the aseptic fill site, track record of batch release, change control robustness, and reserve supply agreements.
References
- (No citable sources were provided in the prompt to support a verified list of named sugammadex sodium suppliers.)
